AYA.AX Artrya Limited (ASX) closes A$4.01 on 21 Jan 2026: AI diagnostics outlook to watch
AYA.AX stock closed at A$4.01 on 21 Jan 2026, down 2.43% on the day. Trading volume was 1,083,569 shares, above the 50-day average of 864,910. Artrya Limited (ASX: AYA) sells the Salix AI platform that flags coronary artery disease from CT scans. We examine price drivers, valuation metrics, technical signals, and model forecasts investors should monitor.
AYA.AX stock: Price action and key market metrics
Artrya closed at A$4.01, with a day range of A$3.80–A$4.05 and year range A$0.56–A$5.24. Market capitalisation stood at A$464,612,000.00 and shares outstanding are 113,320,000.00. The stock is trading above its 50-day average of A$3.91 and 200-day average of A$2.13, indicating recent strength versus its longer-term trend. Price moved –2.43% today after modest profit-taking.
Business model and AI product: Salix and commercial traction
Artrya sells Salix, a cloud-based AI tool for coronary computed tomography angiography. Salix automates detection to prioritise patients at risk of heart attack. The business model mixes SaaS and clinical licensing. Recent commercial updates point to pilot expansions, but recurring revenue remains limited and user adoption is a key near-term growth metric.
AYA.AX stock: Financials, valuation and analyst context
Artrya reports EPS -A$0.18 and a trailing PE of -22.78, reflecting losses. Price-to-book is 19.84 and current ratio is 8.27, showing strong short-term liquidity. Sales per share are minimal, producing a price-to-sales ratio that is elevated. Sector peers trade at higher PE and lower PB, so Artrya sits as a premium valuation on future AI value. Analyst consensus is sparse; the company lists an earnings announcement for 24 Feb 2026.
Technical outlook and trading signals for AYA.AX stock
Momentum indicators show strength and short-term overbought signals. RSI is 70.89 and MFI is 82.92, both in overbought territory. ADX at 40.86 signals a strong trend. Bollinger Bands run A$3.23–A$5.17. Average daily volume of 864,910 compares to today’s 1,083,569, supporting liquidity. Traders should watch a break above A$5.24 for trend continuation or a pullback toward the 50-day average at A$3.91.
Meyka AI rates AYA.AX with a score out of 100 and forecast
Meyka AI rates AYA.AX with a score out of 100: 59.05 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects A$4.06 (monthly), A$6.10 (quarterly) and A$7.30 (12 months). Compared with the current price A$4.01, the 12-month forecast implies +82.09% upside. Forecasts are model-based projections and not guarantees.
Risks, catalysts and practical considerations for AI investors
Key risks include limited revenue scale, negative EPS, and high PB. Clinical validation, regulatory updates, or multi-site contracts are catalysts that could re-rate the stock. The healthcare AI sector outperformance is mixed; Artrya competes with established medical-imaging vendors. Investors should weigh execution risk against potential software margins and clinical adoption milestones.
Final Thoughts
Key takeaways: AYA.AX stock closed at A$4.01 on 21 Jan 2026 on higher-than-average volume. Artrya’s Salix AI positions it in a growth segment of healthcare, but financials show EPS -A$0.18 and a stretched price-to-book 19.84. Technicals are bullish yet overbought, with RSI 70.89. Meyka AI rates the stock 59.05 (C+, HOLD) and models a 12-month target of A$7.30, implying +82.09% upside from today’s price. Investors focused on AI stocks should track commercial rollouts, the 24 Feb 2026 earnings release, and any regulatory approvals. Our view is data-driven, not advice. For ongoing updates visit our Artrya page at Meyka AYA page and review the detailed company profile and market coverage below.
FAQs
What drives AYA.AX stock price movement?
AYA.AX stock moves on clinical adoption, commercial contracts for Salix, trial results, and earnings updates. Market liquidity and sector momentum also affect short-term swings.
What is Meyka AI’s forecast for AYA.AX stock?
Meyka AI’s forecast model projects A$4.06 (monthly), A$6.10 (quarterly) and A$7.30 (12 months). These are model projections and not guarantees.
Is AYA.AX stock overvalued based on financial metrics?
Valuation is stretched: price-to-book 19.84 and negative EPS -A$0.18. High PB reflects investor expectations for AI growth rather than current revenue.
How can investors monitor upcoming catalysts for AYA.AX stock?
Watch the earnings announcement on 24 Feb 2026, clinical validation news, large customer deals, and regulatory updates. Volume and price action around those events matter.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
